I am going to take the opposite side of the argume
Post# of 30028
Posted On: 11/11/2014 1:04:41 PM
I am going to take the opposite side of the argument about uplisting into strength. AMBS has had some real progress made this year. Great. Who knows about it? About 68 total people in the country. To anyone that their only "penny stock" or OTC investment is AMBS let me ask you this: Can you tell me any milestones, PRs, or fundamental changes off the top of your head from any other penny stocks or OTC companies? I know I certainly can't. These PRs are not on anybody's radar. In fact, the only reason why I know about the PR's or news is because my investment client sends real time information notices about any PR's or company updates on my holdings. If it wasn't for that, the only way I would notice AMBS is if I actually went to their webpage and checked manually or signed up for updates.
Now, how is anyone supposed to know to do that, if they don't even know what an Amarantus is? Is it a company, a food, a flower, a brand name of clothing? If no one has heard of the company, how are they going to even know to look for updates or positive material changes? Please do not kid yourself if you believe Amarantus is a household name among investors. Everyone I know personally that is involved with the market has never heard of Amarantus. (This includes people I know that are Biotech heavy.)
Now let's examine the possibility of what could happen if they keep putting off uplisting. All these potential catalysts that are coming up will probably result in more of the same PPS action. What do you think is going to happen when they announce they are finished with APP? Probably more of the same, which includes no volume and a red day. How about if they are granted Orphan designation for MANF RP? The average increase of a Biotech company when they are granted ODD on a drug is 4% the day of the news. That's a fact, not an opinion. Do you think AMBS is going to get 4%? It is probably going to get lost into the wind again because only the serious shareholders are going to know about this. Even the gambling shareholders that just spread money across a bunch of penny stocks and pray probably won't even catch wind of it. (Probably because they just gamble and not invest.)
I say as soon as Amarantus has the dough to uplist without hurting their financial position, they should do so. 80-1, 100-1, I would not care at this point. Get this thing at $8.00 so that when these catalysts are announced in the future, it will support the PPS or even increase it because the news will be disseminated in an ocean, not in a cup of water.
Or there is this scenario: They systematically release PRs and news in the most strategic fashion possible and the PPS somehow reaches .20. The uplist is then done 40-1 and it is $8.00. But now guess what? They have just figuratively and literally blown their load. After the barrage of news and good things which we are waiting for now happens, when is the next time they are going to have a line up of potential catalysts this deep? I fear the PPS will drift down if they wait because the truth is people are just impatient. Who wants to invest in that shiny new toy company that just hit Nasdaq on a RS and then has no material news until it's 10-Q? If there are no momentum drivers for the PPS after the uplist, then what is going to perpetually drive the excitement in this company?
But then of course there is Lympro revenue or JVs. If Lympro revenue is substantial enough (and I mean 8m+ which is about half a year expenses for them) or a JV is formed with upfront cash then obviously nothing I just previous droned on about makes a difference because people are going to start investing in AMBS because their fundamentals have been de-risked with the only really fear: they will not be able to outlast their money or they will continue to debt finance the company into the ground.
So in conclusion if Gerald knows Lympro revenue is going to be much better than the lowball I feel Jason N gave everyone or a JV is locked and loaded at some point, then sure I say wait to uplist. But if these catalysts are going to be their hardest hitting group of PRs released in close proximity for a while, I say uplist now, 100-1.
Now, how is anyone supposed to know to do that, if they don't even know what an Amarantus is? Is it a company, a food, a flower, a brand name of clothing? If no one has heard of the company, how are they going to even know to look for updates or positive material changes? Please do not kid yourself if you believe Amarantus is a household name among investors. Everyone I know personally that is involved with the market has never heard of Amarantus. (This includes people I know that are Biotech heavy.)
Now let's examine the possibility of what could happen if they keep putting off uplisting. All these potential catalysts that are coming up will probably result in more of the same PPS action. What do you think is going to happen when they announce they are finished with APP? Probably more of the same, which includes no volume and a red day. How about if they are granted Orphan designation for MANF RP? The average increase of a Biotech company when they are granted ODD on a drug is 4% the day of the news. That's a fact, not an opinion. Do you think AMBS is going to get 4%? It is probably going to get lost into the wind again because only the serious shareholders are going to know about this. Even the gambling shareholders that just spread money across a bunch of penny stocks and pray probably won't even catch wind of it. (Probably because they just gamble and not invest.)
I say as soon as Amarantus has the dough to uplist without hurting their financial position, they should do so. 80-1, 100-1, I would not care at this point. Get this thing at $8.00 so that when these catalysts are announced in the future, it will support the PPS or even increase it because the news will be disseminated in an ocean, not in a cup of water.
Or there is this scenario: They systematically release PRs and news in the most strategic fashion possible and the PPS somehow reaches .20. The uplist is then done 40-1 and it is $8.00. But now guess what? They have just figuratively and literally blown their load. After the barrage of news and good things which we are waiting for now happens, when is the next time they are going to have a line up of potential catalysts this deep? I fear the PPS will drift down if they wait because the truth is people are just impatient. Who wants to invest in that shiny new toy company that just hit Nasdaq on a RS and then has no material news until it's 10-Q? If there are no momentum drivers for the PPS after the uplist, then what is going to perpetually drive the excitement in this company?
But then of course there is Lympro revenue or JVs. If Lympro revenue is substantial enough (and I mean 8m+ which is about half a year expenses for them) or a JV is formed with upfront cash then obviously nothing I just previous droned on about makes a difference because people are going to start investing in AMBS because their fundamentals have been de-risked with the only really fear: they will not be able to outlast their money or they will continue to debt finance the company into the ground.
So in conclusion if Gerald knows Lympro revenue is going to be much better than the lowball I feel Jason N gave everyone or a JV is locked and loaded at some point, then sure I say wait to uplist. But if these catalysts are going to be their hardest hitting group of PRs released in close proximity for a while, I say uplist now, 100-1.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼